Kedrion Highlights Secondary Immunodeficiencies at IPIC 2025

Kedrion Biopharma, a company specializing in plasma-derived therapies, actively participated in the International Primary Immunodeficiencies Congress (IPIC) 2025 in Prague. This year, Kedrion focused on Secondary Immunodeficiencies (SIDs) within hematologic malignancies through a dedicated Satellite Symposium. Experts, including Prof. Hermann Wolf and Dr. Federica Pulvirenti, addressed challenges and advancements in the field. Emphasizing the clinical complexities of SIDs, particularly in B-cell hematological malignancies, highlighted the necessity for early diagnosis and treatment improvements.

Kedrion's involvement underscores a commitment to fostering collaboration and expanding knowledge within this niche. Complementing the Symposium, Kedrion maintained a strong presence with a booth, three poster sessions, and international delegates. This platform allowed for deeper interaction with medical experts, promoting innovation and sharing expertise. The company's efforts are aligned with improving patient outcomes and ensuring quality care through collaboration between various healthcare stakeholders.